Perspective Therapeutics Inc

Research Perspective Therapeutics Inc (CATX) on Bullrun: market cap USD 375.21M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 375.21M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 103.12M-USD 95.23Mn/a-1.4USD 30.63MUSD 1.63MUSD 207.03M
FY2024USD 0-USD 79.28M-USD 72.71Mn/a-1.23USD 61.58MUSD 1.68MUSD 290.67M
FY2023USD 1.43M-USD 46.51M-USD 37.99M100.0%-1.74USD 9.24MUSD 1.73MUSD 75.18M
FY2022USD 0-USD 10.76M-USD 10.68Mn/an/aUSD 20.99MUSD 392.00KUSD 54.64M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 375.21Mn/an/an/a
20252025-12-31USD 204.43Mn/an/an/a
20242024-12-31USD 225.44Mn/an/an/a
20232023-12-29USD 112.23Mn/an/an/a
20222022-12-30USD 35.53Mn/an/an/a
20212021-12-31USD 55.40Mn/an/an/a

About Perspective Therapeutics Inc

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Perspective Therapeutics Inc's market cap?

Perspective Therapeutics Inc's market capitalization is USD 375.21M.

What does Perspective Therapeutics Inc do?

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.